【摘要】 目的 探讨TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者的临床效果。方法 68例中晚期原发性肝癌患者随机分为两组，对照组实施TACE治疗，观察组实施TACE联合卡瑞利珠单抗治疗，比较两组的近期疗效、肿瘤标志物水平及不良反应。结果 治疗后，观察组的客观缓解率和疾病控制率均高于对照组，CEA、 AFP水平均低于对照组（P <0.05）。结论 TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌可显著提高近期疗效，降低肿瘤标志物水平。更多还原

【Abstract】 Objective To explore the clinical effect of TACE combined with carrelizumab in the treatment of patients with middle-advanced primary liver cancer. Methods 68 patients with middle-advanced primary liver cancer were randomly divided into two groups. The control group was treated with TACE, and the observation group was treated with TACE combined with carrelizumab. The short-term efficacy, levels of tumor markers and adverse reactions were compared between the two groups. Results After treatment, the objective remission rate and disease control rate of the observation group were higher than those of the control group, and the levels of CEA and AFP were lower than those of the control group(P <0.05). Conclusions TACE combined with carrelizumab in the treatment of middle-advanced primary liver cancer can significantly improve the short-term efficacy and reduce the levels of tumor markers.更多还原